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Abstract 
The β-amyloid (Aβ) peptide aggregates into a number of soluble and insoluble forms, with 
soluble oligomers thought to be the primary factor implicated in Alzheimer’s disease (AD) 
pathology. As a result, a wide range of potential aggregation inhibitors have been developed. 
However, in addition to problems with solubility and protease susceptibility, many have 
inadvertently raised the concentration of these soluble neurotoxic species. Sandberg et al 
previously reported a β-hairpin stabilized variant of Aβ42 that results from an intramolecular 
disulphide bridge (A21C/A31C; Aβ42cc), which generates highly toxic oligomeric species 
incapable of converting into mature fibrils. Using an intracellular protein-fragment 
complementation (PCA) approach we have screened peptide libraries using E. coli that harbor 
an oxidizing environment to permit cytoplasmic disulphide bond formation. Peptides 
designed to target either the first or second β-strand have been demonstrated to bind to Aβ42cc, 
lower amyloid cytotoxicity, and confer bacterial cell survival. Peptides have consequently 
been tested using wild-type Aβ42 via ThT binding assays, circular dichroism, MTT 
cytotoxicity assays, fluorescence microscopy, and atomic force microscopy. Results 
demonstrate that amyloid-PCA selected peptides function by both removing amyloid 
oligomers as well as inhibiting their formation. These data further support the use of semi-
rational design combined with intracellular PCA methodology to develop Aβ antagonists as 
candidates for modification into drugs capable of slowing or even preventing the onset of AD. 
 
Impact Statement: β-amyloid (Aβ) aggregates into a number of soluble and insoluble forms, 
with soluble oligomers considered the primary factor implicated in Alzheimer’s disease (AD) 
pathology. We have screened peptide libraries inside bacteria using a toxic conformationally 
restricted form of Aβ. We have derived peptides that bind, lower amyloid cytotoxicity, and 
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confer bacterial cell survival, validating the approach to develop Aβ antagonists as candidates 
for modification into drugs capable of slowing or even preventing the onset of AD. 
 
Keywords: amyloid, protein misfolding, protein-protein interactions, library screening, 
protein-fragment complementation assay, Alzheimer’s disease. 
 
Abbreviations: Aβ42, β-amyloid 1-42 variant; CD, circular dichroism; PPI, Protein-protein 
Interaction; PCA, Protein-fragment Complementation Assay; TEM, Transmission Electron 
Microscopy: MTT, (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ThT, 
Thioflavin-T; PTA, Phosphotungstic acid; HFIP, hexafluoroisopropanol; TFA, trifluoroacetic 
acid. 
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Introduction 
It has been widely speculated that small soluble oligomers of Aβ play a major role in the 
pathology of Alzheimer’s disease (AD) (1-4). However, developing drugs that prevent the 
accumulation of these species has proven difficult. Initial studies that sought to breakdown 
large insoluble oligomers have in some instances led to an accumulation of small toxic 
species (5), while more recent work has shown that even dimers or trimers of Aβ are toxic 
and able to impair synaptic function (6). In screening libraries to identify peptides capable of 
modifying aggregation, an elegant approach would be to lock Aβ42 into a toxic conformation. 
This would ensure population of an oligomeric state that is pathogenically relevant to the 
disease. Sandberg and co-workers previously studied the effect of an intramolecular 
disulphide-bridged double mutant of Aβ42 (A21C/A31C; Aβ42cc) (7). In this approach, 
conservative mutations were used to create a disulphide bridge and force an otherwise 
unstructured and monomeric Aβ42 into the β-hairpin conformation found in mature fibrils. 
The conformation therefore provides the structural basis for subsequent amyloidogenesis (8). 
Disulphide tethering was found to stabilize highly toxic Aβ oligomers that retained the 
conformational and biological properties of wild-type Aβ. Moreover these molecules did not 
go on to convert into mature fibrils and were shown to contain SDS-stable dimeric and 
trimeric species. Experiments using SH-SY5Y human neuroblastoma cells demonstrated that 
Aβ42cc oligomers or protofibrillar species formed by these oligomers were 50 times more 
potent inducers of neuronal apoptosis than amyloid fibrils or samples of monomeric wild-type 
Aβ42, in which toxic aggregates were only transiently formed. 
 A wide variety of approaches have been employed to create amyloid inhibitors, 
including small molecule, antibody, and peptide-based inhibitors. These have ranged from 
those that stabilize the native state, sequester monomers, inhibit amyloid growth, as well as 
those that initiate clearance via chaperones and proteases (see (9) for an overview).  In our 
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own studies, we previously presented a novel variation of the intracellular protein-fragment 
complementation assay (PCA) selection system whereby bacteria were used to screen peptide 
libraries and generate Aβ aggregation antagonists (10) and subsequently their retro-inversed 
analogues (11). During PCA a ‘core recognition element’ Aβ25-35, was used as the target 
since, along with Aβ15-21, it is known to form amyloid fibrils in isolation and instigate amyloid 
formation in the parental protein.  Aβ25-35 was fused to one half of murine dihydrofolate 
reductase (mDHFR) with a peptide library fused to the second half. Library members that 
bound Aβ25-35 resulted in a colony under selective conditions. The most effective binders 
were then further enriched by growth competition to isolate from binders that led to lower 
growth rates. Reduced bacterial growth rates are due to the inherent propensity for Aβ to 
aggregate and lead to increased cytotoxic effects (12; 13). Three outcomes are possible for 
any given library member: 
A. Library members bind Aβ, reduce its toxicity and recombine mDHFR to confer cell 
survival. 
B. Library members bind Aβ and recombine mDHFR but either populate or do not 
prevent population of a toxic species. These result in reduced cell growth relative to 1, 
or cell death.  
C. Library members with no affinity for Aβ and therefore no effect on amyloid formation 
will not recombine mDHFR, resulting in cell death. 
Intracellular selection means no assumptions are made regarding the mechanism of 
antagonist action or which amyloid state becomes populated during selection, aiding the 
removal of molecules with undesirable properties from the library such as those that are too 
hydrophobic hence insoluble, those tagged for degradation, those susceptible to protease 
action, and those that are non-specific.  
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To further strengthen this approach, we report on the use of full length Aβ42cc as the target 
molecule rather than Aβ15-21 or the Aβ25-35 amyloidogenic regions of the molecule used 
previously (10). In this experiment, PCA is undertaken using Aβ42cc under oxidizing 
conditions to ensure that: 
1. During selection the Aβ42cc target is constrained into the β-hairpin structure associated 
with the pathology of the disease 
2. The ‘core recognition elements’ of Aβ42cc associated with instigation of amyloid 
formation remain exposed, largely unmodified, and in the correct conformation. 
3. Aβ42cc is able to form soluble oligomeric structures that are highly toxic and 
associated with AD pathology, thus ensuring that a larger number of structurally 
relevant epitopes are presented relative to larger and/or insoluble fibrils populated in 
the absence of the bridge. 
4. Expressing the increased toxicity variant Aβ42cc raises the sensitivity of the PCA 
relative to Aβ42. This is because cells in scenario B above are predicted to die more 
readily or grow at reduced rates. 
We find the peptides derived using this approach to be capable of binding to the disease 
relevant wild-type Aβ42 and reducing associated amyloid formation. To understand the 
mechanism of peptide action we have studied the effectiveness of peptides and found them to 
be capable of removing pre-formed fibrils as well as preventing amyloid from forming. These 
studies have successfully produced a number of lead peptide sequences that are expected to 
provide a scaffold for future drug candidates.  
 
Results 
We have combined semi-rational design with intracellular selection using amyloid-PCA to 
screen peptide libraries and select Aβ42 aggregation antagonists (14; 15; 10). A disulphide-
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bridged variant of Aβ42, known as Aβ42cc, has been used as the target for library screening 
since it constrains the protein into the β-hairpin structure found in amyloid structures that 
form oligomers associated with AD toxicity (Figure 1). PCA libraries were initially screened 
and selected on M9 minimal agar plates. Following this initial single-step selection, colonies 
underwent competition selection where they were pooled and grown before dilution into 
liquid M9 minimal media. This process was repeated multiple times as passages to select for 
the most effective binding sequence. In this process, 1-2 high affinity binders that inhibit 
amyloid formation and reduce bacterial toxicity were found to display the fastest growth and 
dominate the bacterial pool. The selection process indicated that only a very limited subset of 
library members were able to bind Aβ42cc (<1%) and that these can be further separated 
during competition selection PCA to isolate the most effective binders. DNA sequencing 
continued throughout passaging until selection arrived at one discrete peptide. All subsequent 
aggregation studies were undertaken using Aβ42 since Aβ42cc is not found naturally, with ThT 
binding and TEM data demonstrating that fibrils do not form when the intramolecular 
disulphide bridge is intact (7). We demonstrate that the sequences identified using the Aβ42cc 
target can be transferred to the biologically relevant Aβ42.  
 
Library Generation - PCA was undertaken using an Aβ42cc target with sequences 
corresponding to Aβ15-21 (QKLVFFA) Aβ29-35 (GAIIGLM), and Aβ36-42 (VGGVVIA) as 
library templates. The first of these two regions are known to aggregate into toxic fibrils in 
isolation (16-18) and therefore provided a strong starting point for deriving peptides known to 
bind to Aβ42cc and potentially capable of inhibiting aggregation. The third sequence 
incorporates the two additional C-terminal amino acids (Ile-Ala) that renders Aβ42 much more 
toxic than Aβ40. The first library incorporated four fully randomized residues at positions 17-
20 of Aβ15-21, generating a library size of 160,000 (15QKxxxxA21), and resulted in one winner 
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(cys1521; Table I). Interestingly, this library had previously resulted in no colonies when using 
either Aβ42 or Aβ15-21 as target, suggesting an improved epitope for binding upon introduction 
of the cysteine-bridge. Moreover, the selected sequence, QKVLLFA, bared remarkable 
similarity to the Aβ15-21 (QKLVFFA) parental sequence upon which it was based, having been 
enriched during PCA from four fully randomized residues at positions 17-20.  The Aβ15-21 
peptide has been previously shown to form amyloid in isolation and found to be toxic in MTT 
experiments (19; 20). The second library incorporated four fully randomized positions at 29-
30 and 34-35 of Aβ29-35, with residues 31-33 fixed from a previous selection (10), generating 
a 160,000 member library (29xxKATxx35), and resulted in two amyloid-PCA winners (cys2935a 
and cys2935b; Table I) with no sequence homology to the amyloid template on which they 
were based. The last library fixed residues 38-40 of Aβ36-42 as ‘GVV’ as is found in wild-type 
Aβ40 and Aβ42, but was fully randomized at residues 36-37 and importantly at residues 41-42 
associated with the increased toxicity of Aβ42, generating a 160,000 member library 
(36xxGVVxx42), and resulting in one winner (cys3642; Table I). 
 
Peptide characterization – PCA derived peptide sequences (Table I) were synthesized and 
characterized using a number of experiments that included thioflavin-T (ThT) dye binding, 
circular dichroism (CD), oblique angle fluorescence (OAF) and atomic force microscopy 
(AFM). The results demonstrate that the peptides do not aggregate in isolation, and are able to 
prevent Aβ42 aggregation and/or remove preformed fibrils. In addition, growth competition 
assays using E.coli under PCA conditions in M9 media and an MTT assay using PC12 cells, 
both using the Aβ42 parent peptide, were undertaken to establish cytotoxicity to bacterial and 
mammalian cells. The growth competition experiments simultaneously demonstrate that 
peptides bind to Aβ42 and reduce its associated toxicity during bacterial selection. MTT 
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experiments were used to establish that the toxicity associated with extracellular Aβ42 to 
mammalian cells could be reduced when incubated in the presence of PCA selected peptides.  
Cell Growth Experiments – The effect of inhibitors on the growth of E.coli harboring 
pES300d-Aβ42cc-DHFR2 target and pES230d-antagonist-DHFR1 fusion plasmids as present 
in the final PCA selection round were tested (Figure 2). In this experiment cells were grown 
in a shaking incubator from a starting OD600 of 0.02 under PCA conditions in M9 minimal 
media containing Cm, Amp and Kan to retain target and antagonist expressing plasmids as 
well as pREP4 for expression of the lac repressor. In addition Tmp was included for 
inhibition of bacterial DHFR and IPTG to induce high levels of target and antagonist 
expression. This experiment monitors both mDHFR reassembly, and therefore binding of 
antagonist to the Aβ42cc target, as well as the toxicity of the oligomeric state that is populated. 
As expected, expression of the toxic Aβ42cc did not result in significant levels of growth even 
though the protein is well documented to self-associate (Figure 2). In addition, western blots 
(Figure S5) show that Aβ42cc is expressed in the soluble fraction, suggesting that the protein is 
both soluble and toxic and is therefore populating toxic protofibrillar structures. All four 
antagonists in this study, along with the positive control cJun-FosW, were clearly able to 
restore bacterial growth thereby providing strong evidence for direct binding and reduced 
toxicity in the context of this bacterial selection system. 
 
ThT experiments demonstrate a reduction in amyloid content – To determine the ability of 
PCA derived peptides to prevent fibril assembly (inhibition) or to breakdown preformed 
fibrils (reversal), ThT fluorescence was used as an indicator of the degree to which Aβ42 
aggregates into amyloid fibrils. In these assays, Aβ42 was rendered monomeric (21) and 
freeze-dried before being resuspended and incubated at 37 C, leading to formation of 
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amyloid aggregates. For the inhibition assay, PCA-selected peptides were added on day zero 
and their ability to prevent amyloid formation was assessed after three days. For the reversal 
assay Aβ42 was incubated in isolation for three days to allow amyloid formation before 
addition of peptide, followed by incubation for a further three days to monitor the ability of 
peptides to breakdown amyloid aggregates. In all cases a positive control peptide from the 
literature (iAβ5; (22; 23)) known to perform well in ThT assays was used. Figure 3 shows the 
results of inhibition and reversal experiments for the four single PCA-selected peptides and 
two examples of peptides administered in combination. Both inhibition and reversal 
experiments have been undertaken at five different Aβ42:peptide ratios ranging from 10 fold 
sub-stoichiometric to 10 fold super-stoichiometric. For every peptide, and at the majority of 
stoichiometries, the ThT-bound signal was reduced for both inhibition and reversal 
experiments, indicating that peptides are able to bind Aβ42 and lower the amount of ThT-
bound amyloid in solution. Consistent with previous studies, changes in Aβ42:inhibitor 
stoichiometry altered binding although it was not clear if this was dependent on dose (24; 10). 
However, on average the effects observed at ratios of 1:0.1 are small while ratios of 1:1 are 
lower than 1:2 or 1:4 (see Figure S4). These ratios were required to consistently elicit an 
effect in both inhibition and reversal experiments. Increasing the ratio to 1:10 led to poorer 
levels of inhibition for several peptides (and consequently increased ThT fluorescence). What 
is also clear from these experiments is that ThT-bound amyloid can be frequently reduced to 
less than 50% of the signal found in the Aβ42 positive control, with peptides performing well 
in both inhibition and reversal experiments. Reassuringly, the positive control iAβ5 peptide 
was also able to reduce the ThT signal by >40%. 
 In addition we have conducted experiments where amyloid-PCA derived peptides 
predicted to target different regions of the disulphide tethered Aβ42cc have been combined 
(Figure 3b). These combinations were a) cys1521/cys2935a and b) cys1521/cys3642. In both 
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instances these peptides were derived from libraries based on (and therefore predicted to 
independently target) the first and second strands within the tethered β-hairpin structure of 
Aβ42cc. Indeed, cys2935a is based on a sequence that was selected using the Aβ25-35 target (10), 
with the same library unable to yield any binding sequences when using the wild-type Aβ42 or 
Aβ15-21 as a target. In addition, the library used to generate cys1521 was also unable generate 
any hits against wild-type Aβ42. This is significant since it suggests that Aβ42cc represents a far 
more accessible target for intracellular library screening and antagonist selection. Despite 
this, ThT experiments in which these peptides were combined generated only one instance 
where two peptides assayed together were, within error, consistently more effective across the 
stoichiometries than the average of the individual component peptides (Figure 3b). This was 
observed for inhibition experiments that combined cys1521 and cys2935a. In this case an 
additional 25-35% reduction in ThT fluorescence was observed over the average of the 
individual peptides at 1:0.1, 1:2, 1:4 and 1:10 stoichiometries, indicating a benefit in 
combining them (Figure 3b, green vs. purple). At 1:1, large cumulative errors precluded any 
interpretation. In contrast, combinations of cys1521 and cys3642 gave no consistent benefit in 
inhibition experiments. For peptides tested in combination during reversal experiments, no 
consistent benefit was observed over either peptide assayed alone. Rather, combinations of 
cys1521 and cys2935a displayed signs of synergy at 1:1 to 1:2 molar ratios with the trend 
reversing for 1:4 and 1:10, indicating that higher concentrations of peptide can lead to 
increased ThT fluorescence. Since increasing the molar ratio did not lead to improvements in 
the reversal of amyloid in most cases, this indicated that a 2-fold excess of peptide:Aβ may be 
sufficient to reverse fibril formation. A similar trend was true of combining cys1521 and cys3642 
in reversal experiments. However, in both cases the trend was not observed in inhibition 
assays, perhaps reflecting the fact that more binding sites are available in monomerized Aβ42 
to which inhibitor can bind and therefore remain soluble relative to aged and aggregated 
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samples. Lastly, it cannot be ruled out that the combined peptides do not interact with each 
other; however mixing peptides does not result in any gain in amyloid formation since 
increased ThT signals are not observed. 
 
Circular Dichroism experiments demonstrate a reduction in β-sheet content – Since 
amyloid fibrils are predominately β-sheet, we used CD spectroscopy to provide an end-point 
characterization of the aggregates formed once ThT experiments were complete. Consistent 
with a β-sheet structure, spectra show a negative peak at 218 nm. At higher molar ratios (1:2 
or greater for inhibition and 1:4 or greater for reversal) an additional large minima of up to -
11 millidegrees was observed at 200 nm for the majority of peptides, indicating the adoption 
of a mixture of β-sheet (Aβ42) and random-coil like structures (peptides). This minima was 
noticeably less pronounced for the cys3642 peptide and was not observed for iAβ5, which 
adopted a spectrum consistent with a β-sheet structure at all concentrations.  During CD 
experiments, we observed a decrease in β-sheet content in the majority of samples, supporting 
the ThT data by demonstrating that peptides reduce the global β-sheet content relative to the 
Aβ42 sample and therefore the amyloid content. These experiments therefore suggest that 
peptides can bind Aβ42 and exert their effect by reducing the amount of protein in the amyloid 
form. Lastly, ThT and CD spectroscopy experiments undertaken on peptides in isolation that 
have been incubated at 50 μM for 3 days under conditions identical to those used in 
aggregation assays using Aβ42 demonstrate that peptides do not bind significant amounts of 
ThT, and that the CD signal for all peptides (at 0:1) is consistent with that of a random coil or 
weakly helical conformation.  
 
Oblique Angle Fluorescence Microscopy – Samples used in ThT and CD experiments were 
also imaged using OAF microscopy for both inhibition and reversal experiments. To prevent 
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bias towards any one sample the experiment was carried out blind (25). This technique allows 
for surface associated and stacked aggregates of amyloid fibers to be directly imaged. It was 
possible to assess the amount of protein deposited as amyloid and its morphology. OAF 
experiments were undertaken for both inhibition and reversal at all of the molar ratios assayed 
in ThT experiments (Figure 4). In almost every case, for both inhibition and reversal 
experiments, a reduction in the amount of amyloid was observed relative to Aβ42 incubated in 
isolation under identical conditions. In a number of cases amyloid deposits much smaller in 
size were observed. 
 
Atomic Force Microscopy – Again samples used in ThT and CD experiments were imaged 
using AFM as a second direct qualitative measure of fibril formation (Figure 5). A 
stoichiometry of 1:2 (50 µM:100 µM) was chosen for AFM experiments as this was the 
concentration at which peptide inhibitors were on average deemed to be most effective in ThT 
experiments. AFM was undertaken for both inhibition and reversal experiments on cys1521, 
cys2935a, and cys1521+cys2935a as an additional measure of the extent to which these peptides 
are effective when mixed. A major reduction in the amount of amyloid was observed for all 
samples relative to the Aβ42 control. No fibrils were observed for peptides in the absence of 
Aβ42, either alone or when mixed. For inhibition experiments in the case of cys1521+cys2935a no 
fibrils were observed; with mixing appearing to remove fibrils present for the cys1521 sample. 
For reversal experiments the residual fibrils observed in the cys2935a were also largely 
removed upon mixing with cys1521.  
 
Cell-toxicity experiments - MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide)) cell toxicity experiments were performed using Rat phaeochromocytoma (PC12) 
neuronal-like cells to reflect the nature of toxicity in the disease via the reduction of a redox 
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dye (Figure 6). We assessed the toxicity of extracellular Aβ42 deposits on PC12 cell integrity 
and its amelioration by pre-incubation of Aβ42 with peptides. Cells incubated with buffer 
alone resulted in a reduction of the redox dye MTT, leading to a color change from yellow to 
purple that can be measured by a change at A540. In contrast, incubation of cells with Aβ42 
resulted in a large decrease in cell viability and consequently the ability to reduce MTT, 
leading to a smaller signal change. To study the ability of inhibitors to reverse the effect upon 
cell viability MTT assays were performed with a range of molar ratios relative to Aβ42 and 
normalized relative to cells in isolation (normalized as 0% death) and cells incubated with 
Aβ42 alone (normalized as 100% death). Although the changes are small and the cumulative 
errors resulting from comparatively small changes can be large, we were nonetheless able to 
draw some general conclusions from this assay. In particular we observed that effective 
peptides were able to generate modest reductions in toxicity of 5-20% in the majority of 
cases. Neither cys2935a or cys2935b appeared effective in this assay, displaying almost no 
improvement across all stoichiometries. Cys1521 was able to elicit a small decrease of 5-15% 
in a non-dose dependent manner. Cys3642 demonstrated a decrease across all molar ratios of 
10-20%. A combination of cys1521 + cys2935a or cys1521 + cys3642 did not conclusively lead to 
additional lowering of toxicity (Figure 6b). Although reductions in toxicity greater than the 
average of the component peptides were observed, these were small; 5% for cys1521/cys2935a at 
1:10 and 10% for cys1521/cys3642 at 1:10. At other molar ratios the errors were either too large 
or no additional benefits over Aβ42 alone were observed.  It should be noted that since PCA is 
undertaken inside bacteria it is possible that intracellular selection of peptides that are non-
toxic to E.coli may not be as effective when transferred into a mammalian cell system. There, 
exposure to different off-target interactions and a different protease pool will occur, in 
addition to the necessity for the peptide to function in the extracellular space, where Aβ is 
known to aggregate in the brain. This may explain the discrepancy between the effects on 
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growth rates in E.coli and efficacy in MTT experiments on peptides incubated with PC12 
cells.  
 
Discussion 
We have used an intracellular protein-fragment complementation assay (PCA) combined with 
semi-rational library design to identify peptides that can reverse and inhibit Aβ42 aggregation 
by up to 80% as well as lead to a modest reduction (5-20%) in its toxicity. As a target during 
bacterial selection we utilized a double cysteine mutant Aβ42cc (A21C/A30C, (7)) that has 
been shown to lead to the population of pathogenically relevant soluble oligomers in the 
cytoplasm of an E.coli strain that harbors an oxidizing cytoplasm environment (26; 10). An 
advantage of using PCA with Aβ42cc is that the disulphide bridge forces Aβ into the β-hairpin 
conformation that is associated with toxicity in Alzheimer’s disease. The Aβ42cc mutant has 
been shown to lead to the population of highly toxic oligomers, suggesting that this mutant 
can be used to improve the stringency of the amyloid-PCA assay. In addition, since oligomers 
are adopted, we envisage that this conformationally restricted mutant generates an increase in 
the number of exposed structural epitopes relative to fibrils formed by wild-type Aβ42, 
meaning that more mDHFR activity can be attained within cells harboring binders of this 
disulphide mutant. To target the two β-strands either side of the hairpin, we used Aβ15-21, 
Aβ29-35 and Aβ36-42 as design scaffolds and fully randomized residues at four positions to 
create three libraries of 160,000 members. All three libraries resulted in the identification of 
sequences able to bind the target sequence. In the case of wild-type Aβ42, it should be noted 
that it is possible that the peptide inhibitors may be able to function by stabilizing monomeric 
Aβ42 before it misfolds into the β-hairpin structure, thus preventing conversion into a 
pathogenic structure. By using the restrained Aβ42cc protein, and because we were unable to 
identify full length Aβ42 binders using many of the same libraries, we infer that the wild-type 
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structure is a poor target for antagonist recognition, possibly due to a lack of well-defined 
structural epitopes in the non-amyloid or early oligomeric conformations of the molecule. 
Thus the generalized approach of using Aβ42cc to screen libraries and generate peptide hits 
before testing selected peptides on wild-type Aβ42 is potentially very exciting. 
 
Combination experiments – As previously noted, we have identified hits from the same 15-
21 library that was unable to yield binders for either wild-type Aβ42 or Aβ25-35 target proteins 
(unpublished data). The failure to identify binders in these previous PCA screens suggests 
that the epitope presented was insufficient for effective binding. Thus we believe that the 
restricted conformation of Aβ42 in the disulphide bridged version represents an improved 
target for our ‘recognition-element’ based libraries. Since the 15-21 library was unable to 
provide colonies under PCA conditions with Aβ42, we instead focused our efforts upon the 
25-35 region of the molecule. We therefore envisage that the cys1521 winner is able to target 
the first β-strand in the constrained amyloid conformation of Aβ42cc, with the cys2935 and 
cys3642 libraries targeting the second β-strand. To look for synergy when used in combination 
we therefore incubated the cys1521 winner with either cys2935a or cys3642. In the case of cys1521 
and cys2935a we found a reduction in bound-ThT signal of 20% over the average of the two 
individual peptides, indicating that there is an added benefit in combining peptides, and that 
they may occupy different regions within Aβ. MTT data produced large errors, however 
improvements in cell viability of 5-10% at some molar ratios were observed, indicating that 
the combined effect of the inhibitors is greater than the average of the two. In agreement with 
this, OAF and AFM experiments also suggest that there is an additional benefit in mixing the 
cys1521 and cys2935a peptides.  
This study has led to a number of peptides that are capable of preventing assembly of 
amyloid aggregates as well as breaking down preformed amyloid and further investigation is 
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warranted in the search for molecules that can ultimately slow or even prevent the onset of 
Alzheimer’s disease.  
 
Materials and Methods 
Mutagenesis and Protein Engineering – pES300d-Aβ42cc-DHFR2 was created using overlap 
extension PCR with codon changes corresponding to A21C and A30C. These sites have been 
previously chosen to constrain the peptide into a β-hairpin conformation (7) and are located 
on non-hydrogen bonded sites between β-strands either side of the hairpin and in close 
proximity to each other (27).  
 
Choice of E.coli Strain – Protein-fragment Complementation Assays were undertaken using 
E. coli SHuffle Express cells (New England Biolabs). SHuffle cells have been engineered to 
possess an oxidative cytoplasmic environment that favors disulphide bond formation. In 
particular, SHuffle cells have been engineered to lack thioredoxin reductase (trxB) and 
glutathione reductase (gor) with an additional suppressor mutation (ahpC) which is required 
to restore viability, allowing the formation of stable disulphide bonds in the cytoplasm. Under 
these conditions thioredoxins are in their oxidized state, converting them from reductases to 
oxidases. Proteins that require disulphide bonds for their folding can therefore be oxidized 
and form stable disulphide bonds within the cytoplasm. This cell line also constitutively 
expresses a chromosomal copy of the disulphide bond isomerase DsbC. DsbC promotes the 
correction of mis-oxidized proteins into their correct form (26; 10). 
 
Single Step Selection PCA – pES300d-Aβ42cc-DHFR2 and pREP4 (Qiagen; for expression of 
the lac repressor protein) were co-transformed into SHuffle Express cells (New England 
Biolabs) and plated onto LB agar with the appropriate antibiotics (Kan and Cm). These cells 
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were next made electrocompetent before transformation with the appropriate pES230d-
library-DHFR1 library plasmid (E.coli XL-1 cells were used for construction and cloning of 
libraries, as described previously (14) (10)). Transformed cells were next plated on three 
different media; 1/20th of the cells were plated onto LB agar with three antibiotics (Kan, Amp, 
and Cm) as a positive control of transformation efficiency. A further 1/20th of the solution 
was plated onto M9 minimal medium agar with 1 μg/ml trimethoprim and the same three 
antibiotics as a negative control. Finally, the remaining 90% of transformed cells were plated 
onto M9 minimal agar in the presence of the three antibiotics, 1 μg/ml trimethoprim, and 1 
mM IPTG (isopropyl-β-D-thiogalactopyranoside), to induce expression of the two DHFR 
fragment fused peptides). This single-step PCA selection typically led to approximately 50-
100 colonies from libraries of 160,000 members, meaning that at least 99% of all library 
members are removed at this stage owing to their inability to bind Aβ42cc and reduce toxicity. 
 
Competition Selection PCA - To increase the selection stringency, growth competition 
experiments were undertaken. Using this approach, selected colonies were pooled from the 
plate and grown in M9 minimal media under selective conditions (containing Kan, Amp, Cm, 
trimethoprim and IPTG) and serially diluted over 5-10 passages. Using these sequential 
rounds of competition selection, subtle differences in growth rate are amplified, increasing 
the stringency of selection relative to the single-step method. Competition selection therefore 
allows the most effective 1-2 sequences to be isolated from the 50-100 Aβ42cc binders that are 
initially identified during single step selection. At each passage glycerol stocks were prepared 
and sequencing results were obtained (GATC biotech, London) for DNA pools as well as 
individual colonies. For each passage, 50 μL of liquid culture was added to 50 ml of fresh M9 
minimal media, resulting in an approximate OD600 of 0.01. Cells were incubated at 37°C until 
an OD600 of ~0.4 was reached (typically 2-3 days), before moving to the next passage. 
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Aβ Peptide preparation - Aβ42 was purchased as a pure recombinant peptide from rPeptide 
(Stratech) and was used for all of the experiments described. Prior to use, a quantity of 
peptide was weighed using an analytical balance before being treated to three rounds of 
dissolution in hexofluoro-2-propanol (HFIP), sonication, drying, dissolution in trifluoroacetic 
acid (TFA), sonication and drying, according to the Zagorski protocol (21), and then 
aliquoted into appropriately sized batches for subsequent assays and dried via lyophilisation 
before being dissolved in 10mM potassium phosphate buffer (pH 7.4) to generate a final 
concentration of 50 μM. TFA/HFIP treatment was used to ensure that amyloid growth always 
proceeds from the same monomeric state, thus reducing errors in amyloid formation 
measurements.   
Peptide Inhibitors – Peptides identified using amyloid-PCA (cys1521, cys2935a, cys2935b, 
cys3642, and a positive control from the literature, iAβ5 (22)), were obtained by Peptide 
Protein Research (Fareham, UK) as pure lyophilized peptides. Peptides were weighed using 
an analytical balance and stock solutions of 1 mM concentration were subsequently dissolved 
in ultrapure water. At this concentration (2-200x excess of that used in inhibition and reversal 
experiments) no aggregation or precipitate was observed. In addition bioinformatics tools 
(e.g. Waltz (28), Amylpred (29), Pasta (30), Zyggregator (31), and Tango (32)) do not predict 
that any of the peptides contain amyloidogenic sequences or aggregate in isolation. Lastly, 
CD and ThT experiments upon peptide antagonists in isolation demonstrate that these 
sequences do not bind ThT and form random-coil like species in isolation (see Figure S1).  
Growth Competition Experiments – To confirm that expression of Aβ42cc-DHFR2 fragment 
fusions impedes the growth rate of E. coli, and to ascertain that amyloid-PCA derived 
peptides fused to the DHFR1 fragment are able to reverse this effect, growth competition 
experiments were undertaken. These experiments were performed in M9 minimal media in an 
identical manner to that during the PCA competition selection process. In these experiments 
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(Figure 2) cells expressed either i) Aβ42cc control ii) Aβ42cc + PCA derived peptide or iii) the 
non-toxic control cJun+FosW. The latter PCA-derived pair is known to form a high affinity 
interaction, leading to significant growth rates relative to (i).  
Circular Dichroism (CD) - Far-UV circular dichroism (CD) spectra were recorded on an 
Applied Photophysics Chirascan at 20 °C using the same samples as for ThT experiments. 
Spectra were recorded over the 200-300 nm range at a scan rate of 10 nm/min with step size 
of 1 nm. Spectra were recorded as the average of two scans. Peptide (10 μM in 10 mM 
Potassium Phosphate buffer pH 7.4) was added to a 0.1 cm cuvette (Hellma). Spectra were 
recorded as raw ellipticity.  
Thioflavin T Assays - ThT inhibition assays were performed with 50 μM Zagorski treated 
(21) monomeric Aβ42 in 200 μL of 10 mM potassium phosphate, pH 7.4, with or without each 
peptide inhibitor at a concentration of 5 μM  (for 1:0.1 molar ratio), 50 μM (for 1:1 molar 
ratio), 100 μM (for 1:2 molar ratio), 200 μM (for 1:4 molar ratio), and 0.5 mM (for 1:10 
molar ratio). For the inhibition assays, the target-inhibitor mixtures were incubated together 
on day zero at 37 °C. Single ThT readings were taken on day three at which maximal ThT 
binding was found. For the reversal assays, 200 μL of 50 μM target was incubated alone at 37 
°C for three days before adding to the required amount of lyophilized peptide. The vortexed 
target-inhibitor solutions were then incubated at 37 °C for a further three days, during which 
time single ThT readings were taken on post-mix day three. Experiments were undertaken in 
duplicate and errors expressed as the standard error of the mean. The ThT assay solution was 
prepared from a 25x stock containing 500 μM ThT in 250 mM Tris, pH 7.4. The stock was 
aliquoted and kept frozen until required. It was then allowed to thaw at room temperature for 
10 min before dilution into the appropriate Tris buffer, giving the required freshly prepared 
ThT assay solution containing 20 μM ThT in 10 mM Tris and buffer at pH 7.4.  A total of 
2960 μL of the ThT assay solution was then added into 40 μL of each inhibition/reversal 
21 
 
assay mixture, thoroughly vortexed and transferred into an appropriate cuvette. The 
fluorescence of amyloid-bound ThT was measured by fluorescence spectroscopy using a Cary 
Eclipse fluorescence spectrophotometer; bound ThT exhibits a new excitation maxima at 450 
nm and an enhanced emission maxima at 482 nm (33).  
 
Oblique Angle Fluorescence Microscopy Experiments - Samples were imaged on a custom 
built oblique angle fluorescence system (OAF, (25)). The OAF system permits high signal to 
noise imaging with greater sample depth penetration. Fluorescence imaging was achieved 
through a 500LP dichroic and clean up filter (Chroma, VT USA) before entering an Optosplit 
III triple color image splitter (Cairn, UK), and was detected using an EMCCD camera (Andor 
DU897, Andor, UK). The emission wavelength range used was 500-565nm, therefore both 
the excitation and emission wavelengths were off peak for ThT, however the image quality 
was excellent. All samples were pre-stained with 10μM ThT, pipetted onto a clean glass slide, 
air dried and then imaged in 10 mM potassium phosphate buffer, pH 7.4, supplemented with 
100mM DTT to minimize photobleaching. For consistency and cross-correlation, the same 
samples were used for inhibition/reversal imaging as those in ThT and CD experiments. In 
addition, all OAF experiments were performed blind to prevent bias toward any one sample. 
 
Atomic Force Microscopy Experiments – Samples were imaged in non-contact mode using a 
XE-120 Atomic Force Microscope (Park Systems, South Korea). NSC 15 silicon nitride 
cantilevers  with a spring constant of 40N/m were used for imaging at a scan rate of 1.0 Hz 
and a resolution of 256x256 pixels. All images were taken at room temperature. The AFM 
data were taken from inhibitors alone as well as inhibition and reversal experiments, using 
cys1521, cys2935a, and the cys1521+cys2935a mixture. 5 µL sample was placed on freshly cleaved 
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mica (thickness 0.3 mm). Following adsorption of the protein aggregates (2 mins), the mica 
was washed with 5 mL of double distilled water. Excess water was removed and the samples 
were dried using a stream of nitrogen gas. Samples were immediately analyzed by AFM. 
 
3-(4,5.Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Cell-Toxicity Assay - 
MTT experiments were undertaken using Rat phaeochromocytoma (PC12) cells to assess the 
effect of the toxicity of Aβ42. PC12 cells are known to be particularly sensitive and their use 
in this assay is well established (34). The MTT Vybrant® MTT Cell Proliferation Assay Kit 
(Invitrogen) was used to measure the conversion of the water soluble MTT dye to formazan, 
which is then solubilized, and the concentration determined by a color change monitored via 
absorbance measurement at 570 nm. The change in absorbance can then be converted to a 
percentage MTT reduction which can be used as an indicator of the PC12 cell health in the 
assay. The assay was performed with 10 μM Aβ42 and varying molar ratios of peptide 
corresponding to 1:0.1 (0.1 μM), 1:1 (10 μM), 1:4 (40 μM), 1:10 (100 μM).  PC12 cells were 
maintained in RPMI 1640 +2mM Glutamine medium mixed with 10% Horse Serum, 5% 
Fetal Bovine Serum, supplemented with a 20 mg/mL Gentamicin. Cells were transferred to a 
sterile 96-well plate with 30,000 cells per well and experiments performed in triplicate. 
Briefly, different concentrations of peptides were screened in the presence of 10 μM Aβ42. 
The required volume from peptide and target stock solutions was freeze-dried overnight. The 
freeze-dried peptide and Aβ42 target were resuspended in 100% dimethyl sulfoxide (DMSO), 
each at 100x stock concentration (i.e. 1 mM,  2 mM, 4 mM or 10 mM). For example for the 
molar ratio 1:1 a total of 5 μL from each of the resuspended inhibitor/DMSO and 
target/DMSO was mixed in a well of a 96-well preparation plate, thus giving 10 μL of 1:1 
mM inhibitor/target concentration ratio in 100% DMSO. A total of 90 μL of RPMI media was 
added to the 10 μL inhibitor/target mixture (100:100 μM inhibitor/target ratio in 10% 
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DMSO). A total of 10 μL of the 50:50 μM inhibitor/target mixture in 10% DMSO was then 
dispensed into 90 μL of media/PC12 cells, at final peptide inhibitor and target concentrations 
of 10 μM. These were incubated for 24 h at 37 °C, 5% CO2, prior to the addition of the MTT 
dye. A total of 10 μL of the dye was added to each well and incubated for a further 4 h at 37 
°C, 5% CO2. A total of 100 μL of the DMSO (stop/solubilization solution) was then added to 
each well and was allowed to stand for 10 minutes. The absorbance was measured at 570 nm 
using a 96-well Versamax tunable microplate reader. Assay values for incubation with buffer 
were taken as 100%, and inhibition of cell function by incubation with buffer containing Aβ42 
alone taken as 0%. Raw data were then scaled as follows: (raw data point – Aβ42 
mean)/(buffer mean - Aβ42 mean) x 100. The scaled mean for each data set was then plotted 
with the error given by the standard deviation.  
 
Electronic Supplementary Information 
Five figures showing circular dichroism spectroscopy and ThT experiments undertaken on 
peptides in isolation and together with Aβ42 in both inhibition and reversal experiments, ThT 
Inhibition and Reversal data at a range of molar ratios ranging from sub- to super-
stoichiometric, and western blot analysis of the 6xHis-Aβ42cc-DHFR2 fusion protein 
expressed during PCA. 
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Figure Legends 
Figure 1: The Protein-fragment Complementation Assay for amyloid systems. Selection is 
undertaken using SHuffle cells that harbor an oxidising cytoplasmic environment to promote 
disulphide bond formation. Library members that bind to Aβ42cc lead to the recombination of 
murine DHFR and lead to a colony under selective conditions (bacterial DHFR is specifically 
inhibited using trimethoprim). Subsequent competition selection in liquid media isolates 
winners of highest efficacy. Those library members that bind the target and are able to confer 
faster growth rates by reducing the toxic effects of the amyloid protein most effectively will 
be selected. Since the assay is performed in the cytoplasm of E.coli, any non-specific, 
unstable, aggregation prone (insoluble), protease susceptible members are removed. 
 
Figure 2: To confirm that expression of Aβ42cc-DHFR1 /Aβ42cc-DHFR2 fusions impedes the 
growth rate of E. coli, and to ascertain substitution with antagonist-DHFR1 fusions are able to 
reverse this effect, growth competition experiments were undertaken in M9 liquid media in an 
identical manner to that during the PCA selection process. In these experiments cells 
expressed either i) Aβ42cc + Aβ42cc ii) Aβ42cc+ antagonist or iii) non-toxic cJun+FosW. In this 
experiment only scenarios ii) and iii) led to significant growth rates in E.coli, providing 
evidence that a high affinity interaction is formed and that toxicity associated with expression 
of Aβ42cc has been lowered, leading to significant growth rates relative to i). 
 
Figure 3: ThT Inhibition and Reversal data for a) individual peptides and b) peptides used in 
combination. The data show the effects of different stoichiometries of the inhibitors cys1521, 
cys2935a, cys2935b, cys3642, cys1521+cys2935a, cys1521+cys3642, and iAβ5 on the aggregation of 
50μM Aβ42. The assay was undertaken at three days for the inhibition assay. For the reversal 
assay Aβ42 was incubated in isolation before addition of peptides on day three with the assay 
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undertaken on day six. The assay was performed at 10 μM Aβ42 concentrations. All errors are 
expressed as the standard error of the mean. 
 
Figure 4:  Oblique Angle Fluorescence (OAF) Microscopy data for all inhibitors at all 
stoichiometries. During inhibition experiments, Aβ42 was grown with inhibitor for three days 
and assayed for peptide induced inhibition of amyloid formation. During reversal 
experiments, Aβ42 was grown with inhibitor for three days, after which inhibitor was added at 
a stoichiometry of 1:1 and followed by a further three day incubation to assay for peptide 
induced reversal of amyloid deposition. Each sample was then imaged by fluorescence 
microscopy and panels showing representative images obtained. To quantify amyloid 
deposition the mean grey value over a 256 x 256 (13 μm x 13 μm) area randomly chosen for 
five separate images is plotted as fluorescence intensity. Each data point is scaled to 
overcome the ‘background noise’ by taking Aβ (1:0) as the maximum and iAβ5 as the 
minimum (i.e. (signal-iAβ5)/(Aβ42-iAβ5)). This defines the range over the positive and 
negative controls.  
 
Figure 5: Atomic Force Microscopy (AFM) data. To demonstrate that inhibitors cys1521, 
cys2935a, and cys2935a+cys1521 do not aggregate in isolation, they were grown alone for three 
days at a concentration of 100 µM (i.e. 0:2 molar ratio) under the same conditions as 
inhibition experiments. In all cases no fibril formation was observed. Inhibition experiments 
were undertaken at an Aβ42:inhibitor stoichiometry of 1:2 (row two). In this experiment the 
same sample was used as for ThT experiments, in which Aβ42 was grown with inhibitor for 3 
days at 37°C. All of the peptides are inhibitory, in particular the combination of 
cys2935+cys1521. For reversal experiments, Aβ42 was grown alone for three days, after which 
inhibitor was added at a stoichiometry of 1:2 and followed by a further three days incubation 
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to assay for peptide induced reversal of amyloid deposition. Each of the samples were imaged 
by AFM and panels showing representative images obtained. Also in reversal experiments, it 
can be clearly observed that for all of inhibitors there is a reduction of fibril, although this is 
less pronounced than for inhibition experiments. Scale bars are shown. 
 
Figure 6: Shown are a) the results from the MTT toxicity assay using Aβ42 and selected 
inhibitors using different molar ratios after 24 hours of incubation with PC12 cells. The assay 
was performed with 10 μM Aβ42 and different concentrations of inhibitor, for example, 1:0.1 
(1 μM ), 1:1 (10 μM), 1:4 (40 μM), 1:10 (100 μM). b) a comparison of the MTT results for 
individual peptides against those used in combination. All errors are expressed as the standard 
error of the mean. 
 
Figure 1. 
31 
 
 
 
32 
 
 
 
33 
 
 
 
 
